LORVIQUA Film-coated tablet Ref.[7603] Active ingredients: Lorlatinib

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Product name and form

Lorviqua 25 mg film-coated tablets.

Lorviqua 100 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet (tablet).

Lorviqua 25 mg film-coated tablets: Round (8 mm) light pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.

Lorviqua 100 mg film-coated tablets: Oval (8.5 × 17 mm) dark pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side.

Qualitative and quantitative composition

Lorviqua 25 mg film-coated tablets: Each film-coated tablet contains 25 mg of lorlatinib.

Excipient with known effect: Each film-coated tablet contains 1.58 mg of lactose monohydrate.

Lorviqua 100 mg film-coated tablets: Each film-coated tablet contains 100 mg of lorlatinib.

Excipient with known effect: Each film-coated tablet contains 4.20 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Lorlatinib

Lorlatinib is a selective, adenosine triphosphate (ATP)-competitive inhibitor of ALK and c-ros oncogene 1 (ROS1) tyrosine kinases.

List of Excipients

Tablet core:

Microcrystalline cellulose
Calcium hydrogen phosphate
Sodium starch glycolate
Magnesium stearate

Film-coating:

Hypromellose
Lactose monohydrate
Macrogol
Triacetin
Titanium dioxide (E171)
Iron oxide black (E172)
Iron oxide red (E172)

Pack sizes and marketing

OPA/Al/PVC blisters with aluminium foil backing containing 10 film-coated tablets.

Lorviqua 25 mg film-coated tablets: Each pack contains 90 film-coated tablets in 9 blisters or 120 film-coated tablets in 12 blisters.

Lorviqua 100 mg film-coated tablets: Each pack contains 30 film-coated tablets in 3 blisters.

Not all pack sizes may be marketed.

Marketing authorization holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Marketing authorization dates and numbers

EU/1/19/1355/001
EU/1/19/1355/002
EU/1/19/1355/003

Date of first authorisation: 6 May 2019

Drugs

Drug Countries
LORVIQUA Austria, Australia, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.